Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
Verastem Oncology (Nasdaq: VSTM) has announced its participation in the Stifel 2023 Virtual Targeted Oncology Days, scheduled for April 25, 2023, at 2:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived replay of the presentation will be made available on the same website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005208/en/
Investors:
Investor Relations
+1 781-469-1694
dcalkins@verastem.com
+1 212-600-1902
nate@argotpartners.com
Media:
Corporate Communications
+1 (781) 292-4205
lbuffington@verastem.com
Source: Verastem Oncology